Table 2 Summery of In vivo studies and results
Author, year, Country | Mouse model | Isoform | Results |
|---|---|---|---|
May, R. 2008, USA | C57 Bl/6 | DCLK1-L | Induce tumor proliferation |
May, R. 2009, USA | C57 Bl/6 | DCLK1-L | Promote quiescent and increase survival |
Nakanishi, Y. 2012, Japan | APC Min+ | DCLK1-L/S | Introduce DCLK1 as a distinguished CRC-CSC marker and a tumor initiation factor |
Roy B.C. 2019, USA | APC++ | DCLK1-L/S | Promote tumor initiation and development |
Westphalen, C. B. 2014, USA | BAC-CreERT–dependent genetic lineage–tracing strategy | DCLK1-L | Induces tumor initiation |
Chandrakesan, P. 2015, USA | DCLK1- CreER;Rosa26-YFP | N/A | Induced tumorigenesis, pro-survival, and quiescence |
Chandrakesan, P. 2014, USA | APC Min/+ | N/A | Induced tumorigenesis, pro-survival, and quiescence |
Femia, A. P. 2013, Italy | F344 rats | DCLK1-L/S | More neoplastic function of LGR-5 in comparison with MSA-1 and DCLK1 in normal colon mucosa, precancerous lesions, and adenoma tumors |
O’Connell, M. R. 2015, USA | Friend Virus B NIH (FVB/N) | DCLK1-S | Important function of DCLK1-S in tumor proliferation and metastasis compared with DCLK1-L |
Sureban, S. M. 2011, USA nano | Athymic nude mice (NCr-nu/nu) | DCLK1-L/S | Thargeted-therapy by Nanoparticle delivery |
Sureban, S. M. 2020, USA cart | NOD Scid gamma (NSG) | DCLK1-L/S | Thargeted-therapy by CAR-T cell therapy |